Quent Capital LLC bought a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,800 shares of the biopharmaceutical company’s stock, valued at approximately $82,000. A number of other hedge funds and other […]
Guggenheim Capital LLC bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 36,042 shares of the biopharmaceutical company’s stock, valued at approximately $1,747,000. Several other large investors […]
Complete Response Letter States that GALACTIC-HF Alone Does not Establish Substantial Evidence of Effectiveness Sufficient for Approval Company Expects to.
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) CEO Robert I. Blum sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $42.43, for a total transaction of $424,300.00. Following the completion of the transaction, the chief executive officer now directly owns 406,412 shares […]